Rafał W.
- Country
- Poland
- Department
- Oddział Urologiczny z Pododdziałem Urologii Onkologicznej
Research Overview
Data & Insights
Has run more than one trial at 0 of 28 partner sites.
Specializations
Cardiovascular Therapeutics
Advances the treatment and prevention of ischemic heart disease and related vascular disorders.
- Acute Coronary Syndrome
- Heart Failure with Preserved Ejection Fraction
- Atrial Fibrillation
- Elevated Lipoprotein(a)
- Hypertension
Research targets reduction of major adverse cardiovascular events and improvement of cardiac remodeling.
Oncology – Advanced Solid Tumors
Investigates systemic therapies for high‑risk solid malignancies across multiple organ sites.
- Non‑Small Cell Lung Cancer
- Small Cell Lung Cancer
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer (HR‑positive, HER2‑negative)
- Colorectal Cancer
Efforts emphasize targeted agents, immunotherapy combinations, and biomarker‑driven strategies.
Urologic Oncology
Specializes in malignancies of the urinary tract, particularly bladder and kidney cancers.
- Muscle‑Invasive Bladder Cancer
- High‑Risk Non‑Muscle Invasive Bladder Cancer
- Renal Cell Carcinoma
- Metastatic Castration‑Resistant Prostate Cancer
- Metastatic Hormone‑Sensitive Prostate Cancer
Clinical work integrates intravesical therapies, systemic immunomodulators, and precision oncology approaches.
Metabolic and Obesity‑Related Cardiovascular Risk
Explores the intersection of metabolic disorders and heart disease, focusing on obesity‑driven cardiovascular pathology.
- Obesity and Overweight
- Heart Failure with Reduced Ejection Fraction
- Cardiometabolic Inflammation
- Elevated Lipoprotein(a) Levels
- Hypertension in Obese Populations
Studies aim to mitigate cardiovascular events through metabolic modulation and anti‑inflammatory strategies.
Hepatobiliary and Gastrointestinal Oncology
Targets malignancies of the liver, biliary system, and upper gastrointestinal tract, emphasizing molecularly defined cancers.
- Cholangiocarcinoma (Intra‑ and Extrahepatic)
- Gallbladder Cancer
- FGFR‑Positive Bladder Cancer
- FGFR2b‑Overexpressing Gastric Cancer
- Advanced Hepatocellular Carcinoma
Research integrates targeted inhibitors, antibody‑drug conjugates, and combination regimens to improve survival outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.